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Abstract To establish whether C-reactive protein (CRP)
is an independent predictor of all-cause mortality and
hospitalization in chronic obstructive pulmonary disease
(COPD), we followed 200 patients with COPD and 201
age- and gender -matched controls for a median time of
4.2 years (range, 0.2–5.1 years). Airflow obstruction was
rated moderate if forced expiratory volume in one second
(FEV1) was 50–69% of the predicted value, or severe if
FEV1 was \50%. The CRP level was categorized as low
(B3 mg/L) or high ([3 mg/L). The hazard of death was
estimated by a proportional hazard regression model, using
controls with low CRP as the reference category. Fifty
subjects died: 41 (21%) among the COPD and 9 (4%)
among the controls (p \ 0.0001). The hazard of death in
moderate COPD was not significantly higher than in the
reference category, independently of the CRP level. In
severe COPD with a low CRP, the hazard of death is 3.4
times higher than in the reference category (p = 0.008); in
severe COPD and a high CRP it is 9.6 times higher
(p \ 0.0001). The rate of hospitalization in COPD patients
with a high CRP is 1.9 times higher than in those with a
low CRP [95% confidence interval (CI), 1.2–3.2]. In severe
COPD, it is 6.9 times higher than in moderate COPD (95%
CI, 3.8–12.7). A high CRP level is a significant amplifier of
the risk of death only in severe COPD. The degree of
airflow obstruction is a strong independent predictor of
COPD-related outcomes.
Keywords C-reactive protein  Chronic obstructive
pulmonary disease  Survival
Introduction
Chronic obstructive pulmonary disease (COPD) is a major
cause of morbidity, mortality, and disability in industrial-
ized countries [1]. Chronic airflow obstruction, the func-
tional hallmark of COPD, is associated with an
inflammatory response of the lung to inhaled noxious
particles and gases. COPD also features a systemic
inflammatory component characterized by muscle wasting
and weight loss [2, 3].
C-reactive protein (CRP) is a marker of systemic
inflammation that can be measured in the plasma inex-
pensively. The CRP level is increased in stable COPD
patients with respect to control smokers and non-smokers
[4]. In advanced COPD, elevated CRP levels are associated
with impaired energy metabolism and reduced exercise
capacity [5]. Also, an increased CRP level may be pre-
dictive of adverse cardiac events [6] and of all-cause
mortality in patients with mild to moderate COPD [7]. In a
population-based survey, the CRP level was found to be an
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independent predictor of future adverse outcomes in sub-
jects with airway obstruction [8].
The present study was undertaken to reappraise CRP as
an independent predictor of all-cause mortality and hospi-
talization for COPD exacerbation. We followed over time a
sample of patients with moderate to severe COPD, and an
equal size sample of age- and gender -matched controls
who took part in a multicenter cohort study on genetic
susceptibility to the development of COPD.
Methods
Sample
The study sample included 200 patients with COPD and
201 controls that were part of a larger cohort enrolled in a
case–control study aimed at assessing genetic susceptibility
to the development of COPD [9–11].
The subjects, all Caucasian, were evaluated at the out-
patient clinic of the CNR Institute of Clinical Physiology,
Pisa, Italy, between November 1, 2001 and September 30,
2003. Potential candidates were enrolled through the help
of family physicians in the city of Pisa and surroundings.
Criteria for case recruitment were (a) the firm clinical
diagnosis of stable COPD, (b) airflow limitation as indi-
cated by a post-bronchodilator ratio of forced expiratory
volume in one second over forced vital capacity (FEV1/
FVC) \ 0.7 and FEV1 B70% of the predicted value [12],
and (c) a smoking history C20 pack-years.
Patients were excluded from the study if they had an
established diagnosis of asthma, established obstructive
syndromes other than COPD or lung cancer, history of
atopy, known alpha-1-antitrypsin deficiency, or a serum
alpha-1-antitrypsin concentration\1.0 g/dL. Patients were
also excluded if they had had a clinically confirmed acute
exacerbation in the 4 weeks preceding the study entry.
By study design, controls were recruited to match COPD
patients on age and gender. All the controls were current or
former smokers with a smoking history C20 pack-years.
Only individuals with no airflow obstruction were included
in the control group (FEV1/FVC [ 0.7; FVC and
FEV1 [ 80% of the predicted value). Individuals were
excluded from the control group if they had a history of
chronic lung disease or atopy, a family history of COPD, or
had had an acute respiratory infection in the 4 weeks pre-
ceding the study entry.
Study protocol
The protocol was approved by the local ethics committee.
Before entering the study, an informed written consent was
obtained from all the subjects.
Detailed clinical history and physical examination were
obtained in each participant. Comorbid conditions were
defined as follows:
Systemic arterial hypertension was considered to be
present if there was documented persistent elevation of
arterial pressure (systolic [150 mmHg or diastolic
[90 mmHg), or if the patient was receiving anti-hyper-
tensive medication. Ischemic heart disease was considered
to be present if one of the following criteria were met:
(a) typical angina on exertion, (b) use of anti-anginal
medication, and (c) any prior myocardial infarction docu-
mented by electrocardiogram and cardiac enzyme eleva-
tion. Left heart valvular disease was recorded if there was
hemodynamic or echocardiographic evidence of mitral or
aortic stenosis or incompetence. Heart failure was recorded
if there was echocardiographic evidence of a left ventric-
ular ejection fraction B40%. Chronic cor pulmonale was
recorded if there was radiologic or echocardiographic
evidence of dilatation of the right heart cavities. Right
ventricle hypertrophy was considered to be present if the
thickness of the right ventricle free wall exceeded 7 mm on
2-D echocardiography.
Cerebrovascular disorders included transitory ischemic
attacks (TIA) and stroke and were recorded if documented
any time prior to the enrollment in the study. Pulmonary
embolism was recorded if there had been episodes of
embolism, diagnosed by lung scintigraphy or computed
tomographic angiography, that required anticoagulant
therapy. Similarly, deep vein thrombosis was recorded if
there had been episodes of venous thrombosis, documented
by compression ultrasonography of the lower or upper
extremities, requiring anticoagulant therapy.
Diabetes mellitus was considered to be present if the
patient was on long-term therapy with insulin or oral
hypoglycemic drugs. Hypercholesterolemia was recorded
if the blood cholesterol was higher than 200 mg/dL and
the HDL cholesterol lower than 40 mg/dL, or if the
patient was on long-term statin therapy. Hypertriglyceri-
demia was recorded if triglyceride levels were higher than
150 mg/dL. Hypercholesterolemia and hypertriglyceride-
mia were grouped under the term dyslipidemia. Docu-
mented hyper- or hypothyroidism of any cause requiring
appropriate medical treatment was recorded as thyroid
dysfunction. Chronic hepatitis C was recorded if there
were elevated serum aminotransferases for longer than
6 months, anti-HCV antibodies present in serum, and
positive testing for HCV RNA by polymerase chain
reaction.
Lung function studies included the measurement of FVC
and FEV1 (before and after bronchodilator), and of single
breath carbon monoxide lung diffusing capacity (DLCO).
Spirometry, and DLCO measurements were performed
according to ATS/ERS standards [13, 14].
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Postero-anterior and lateral digital chest radiographs
were obtained in all the subjects at the time of recruitment
into the study and were examined by two pulmonologists
for the presence of emphysema [15]. The diagnosis of
emphysema on chest radiography was based on the iden-
tification of at least two of four explicit criteria that had
been originally validated against lung pathology [16]. The
COPD patients were also invited to complete a self-
administered quality-of-life questionnaire [17].
Upon inclusion, a blood sample (stored in lithium hep-
arin) was obtained from all the subjects for genomic
studies. Plasma aliquots were stored at -80C until further
processing. The CRP level was measured with the high-
sensitivity assay (Immulite, Diagnostic Products Corpora-
tion, Los Angeles, CA, USA).
Follow-up
The 401 sampled subjects were followed up until death or
December 31, 2006, whichever occurred first. All the
subjects were interviewed by phone at 6-month intervals.
Whenever required, their family physicians were also
called. Patients with COPD were evaluated clinically once
a year at the outpatient clinic of our Institution. Critical
events recorded by the physicians in charge of follow-up
included hospital admissions for exacerbation of COPD,
and death. The cause of death was established by reviewing
clinical files, autopsy findings, or death certificates.
Statistical analysis
Continuous variables in the text and in the tables are
reported as median with interquartile range (IQR). Differ-
ences between and within groups were tested for by
Mood’s median test or Fisher exact test.
To model the hazard of death from any cause, we esti-
mated a semi-parametric proportional hazard regression
model. We considered time from study entry to death or
censoring. The continuous variables CRP and FEV1 (as %
predicted) were grouped into classes as follows:
(a) CRP B 3 mg/L (low CRP; N = 222), (b) CRP [ 3 mg/
L (high CRP; N = 179), (c) FEV1 \ 50% (severe airflow
obstruction; N = 78), (d) FEV1 between 50 and 69%
(moderate obstruction; N = 122), and (e) FEV1 above 80%
with FEV1/FVC [ 0.7 (no obstruction; N = 201). They
were introduced in the model along with their interaction
by means of indicator variables.
Since cases and controls were matched on age and
gender, we included a shared frailty term to account for the
potential dependency within each matched pair. The frailty
term, a multiplicative random effect for the baseline hazard
associated with each matched pair, was assumed to follow
a Gamma distribution with the mean equal to one and
unknown variance [18].
The regression coefficients associated with the covari-
ates were tested by likelihood ratio tests. Testing for
homogeneity across matched pairs was performed by
testing that the variance of the frailty term was equal to
zero. To adjust for the boundary constraint, the variance
being non-negative, we compared the likelihood ratio test
statistic with the 50:50 mixture distribution of the Chi-
square with one degree of freedom and the constant zero
[19]. Though this procedure has been shown to be con-
servative [20], with our data it rejected the null hypothesis
of homogeneity across matched pairs.
Among the 200 cases with moderate or severe COPD no
matching was present. The incidence rate of hospitalization
among the cases was modeled by Poisson regression. The
estimates were adjusted for the different length of time of
follow-up (exposure time) across the patients by intro-
ducing the logarithm of the exposure time as an offset
variable in the model.
The dichotomous variable CRP was kept in both the
proportional hazard and the Poisson regression model. All
the remaining variables were included one at a time to
check whether they might be confounders (change in the
regression coefficient after inclusion greater than 10%), or
effect modifiers (statistically significant interaction of the
effect of CRP on the dependent variables). No confounders
were found. The interaction between CRP and the severity
of airflow obstruction was found to be significant in the
proportional hazard regression. p values of less than 0.05
were considered statistically significant throughout. The
statistical analysis was performed with Stata version 10
(StataCorp, College Station, TX).
Results
The baseline characteristics of the study sample are
reported in Table 1.
The CRP concentration in the plasma was significantly
higher in COPD patients than in age- and gender -matched
controls (Table 1). Among the patients with COPD, there
was no significant difference in CRP levels between those
who were on inhaled corticosteroid therapy (median
3.0 mg/L, IQR 1.4–7.4), and those who were not (median
2.8 mg/L, IQR 1.2–6.5) (p = 0.883). Similarly, there was
no significant difference in CRP levels between COPD
patients who were on statin therapy (median 4.5 mg/L,
IQR 1.8–9.2), and those who were not (median 2.8 mg/L,
IQR 1.3–6.6) (p = 0.366).
The sample median follow-up time was 4.22 years
(range, 0.18–5.13 years). During follow-up, 50 subjects
died: 41 (21%) among the 200 patients with COPD and 9
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(4%) among the 201 controls. Overall, the 401 subjects
provided 1,626.7 person-years of follow-up.
The causes of death in the study sample are given in
Table 2. Thirty-eight (76%) of 50 deaths were in-hospital
deaths. COPD was considered the primary cause of death
in 13 (32%) of 41 fatal events in the COPD group.
In univariate analysis, the COPD patients who died were
significantly older and had more severe airflow obstruction
than those who survived (Table 3). The COPD patients
who died also had a significantly lower body mass index, a
higher prevalence of emphysema and of chronic cor pul-
monale, and a worse quality of life than those who survived
Table 1 Baseline characteristics of the study sample
Characteristics Number (%) or median (IQR) p value
COPD (N = 200) No COPD (N = 201)
Age (years) 66 (61–70) 65 (61–70) 0.258
Male sex 178 (89) 172 (86) 0.369
Obesity (BMI [30 kg/m2) 60 (30) 54 (27) 0.508
Current smoker 97 (49) 101 (50) 0.766
Pack-years of smoking 48 (39–60) 40 (33–50) \0.001
FEV1, % predicted 54 (42–65) 95 (88–105) \0.001
DLCO, % predicted 76 (58–86) 96 (86–108) \0.001
Chronic mucous hypersecretion 116 (58) 46 (23) \0.001
Chronic cor pulmonale 47 (24) 0 (0) \0.001
Emphysema 82 (41) 0 (0) \0.001
Comorbidity
Systemic arterial hypertension 95 (48) 75 (37) 0.043
Coronary artery disease 59 (30) 55 (27) 0.659
Heart failure 23 (12) 13 (6.5) 0.083
Dilated cardiomyopathy 6 (3) 6 (3) 1.000
Left heart valvular disease 8 (4) 5 (2.5) 0.416
Chronic atrial fibrillation 10 (5) 7 (3.5) 0.470
Prior stroke 2 (1) 3 (1.5) 1.000
Prior PE or DVT 5 (2.5) 3 (1.5) 0.503
Diabetes mellitus 22 (11) 30 (15) 0.298
Dyslipidemia 61 (31) 74 (37) 0.205
Thyroid dysfunction 18 (9) 11 (5.5) 0.183
Chronic hepatitis C 7 (3.5) 9 (4.5) 0.799
At least one comorbidity 161 (81) 143 (71) 0.036
CRP (mg/L) 3.0 (1.3–7.2) 2.3 (1.1–4.9) 0.006
Therapy
Inhaled bronchodilators 139 (70) 0 (0) \0.001
Inhaled corticosteroids 128 (64) 0 (0) \0.001
Theophylline 48 (24) 0 (0) \0.001
Long-term oxygen 7 (3.5) 0 (0) 0.007
Cardiovascular drugs 122 (61) 108 (54) 0.158
Diuretics 52 (26) 30 (15) 0.006
Warfarin 15 (8) 10 (5) 0.311
Statin 37 (19) 47 (23) 0.269
Oral hypoglycemic drugs/insulin 17 (9) 21 (10) 0.609
Thyroid replacement therapy 7 (3.5) 4 (2) 0.380
Differences between COPD and no COPD are assessed by Fisher exact test or Mood’s median test
IQR interquartile range, BMI body mass index, FEV1 forced expiratory volume in one second, DLCO diffusing capacity of the lung for carbon
monoxide, PE pulmonary embolism, DVT deep vein thrombosis, CRP C-reactive protein
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(Table 3). There was no difference across the two groups
as regards the baseline plasma concentration of CRP level
(Table 3).
The results of the proportional hazard regression model
are given in Table 4. In this analysis, the control subjects
with low CRP levels are the reference category.
For the patients with moderate COPD, the hazard of
death from any cause was not significantly higher with
respect to the reference category, independently of the CRP
concentration. In the patients with severe COPD and a low
CRP level, the hazard of death was 3.4 times higher than in
the reference category. High CRP level was an effect
amplifier in the patients with severe COPD such that the
hazard of death in this category was nearly tenfold higher
than in the reference category.
Kaplan–Meier survivor curves in the patients with
COPD are displayed in Fig. 1.
In severe COPD and a high CRP level, the cumulative
rate of death from any cause was significantly higher than
in those with severe obstruction and a low CRP level. In
moderate COPD, there was no significant difference in the
mortality rate between the patients with high and those
with low CRP levels.
The incidence rate of hospitalization for COPD exac-
erbation was 1.9-fold higher in the patients with a high
CRP level than in those with a low CRP level (95% CI,
1.2–3.2, p = 0.012). In the patients with severe COPD, the
incidence rate of hospitalization was 6.9-fold higher than in
those with moderate COPD (95% CI, 3.8–12.7,
p \ 0.0001). The interaction between the covariates (CRP
and FEV1) was not statistically significant.
Discussion
The primary objective of the present study was to establish
whether an elevated CRP level is an independent predictor
of all-cause mortality in established COPD. Differently
Table 2 Causes of death in the study sample
Cause of death Number of deaths p value
COPD No COPD
Sudden death 8 2 0.062
Acute myocardial infarction 2 1 0.623
Other cardiovascular deathsa 4 1 0.215
Hemorrhagic shock 1 0 0.499
Respiratory failure 13 0 \0.0001
Pneumonia or sepsis 6 1 0.068
Cancerb 7 4 0.380
All-cause deaths 41 9 \0.0001
Differences between COPD and no COPD are assessed by Fisher
exact test
a Irreversible cardiac arrhythmia (N = 2), rupture of cardiac aneu-
rysm (N = 1), stroke (N = 1), death during heart transplantation
(N = 1)
b Lung carcinoma (N = 4), liver carcinoma (N = 3), colon carci-
noma (N = 2), gastric carcinoma (N = 1), lymphoma (N = 1)
Table 3 Characteristics of 200 COPD patients in relation to survival
Characteristic Number (%) or median (IQR) p value
Survived (N = 159) Died (N = 41)
Age (years) 64 (61–69) 71 (68–73) \0.0001
Male sex 139 (87) 39 (95) 0.261
BMI (kg/m2) 28 (25–31) 25 (23–29) 0.024
Pack-years of smoking 47 (38–59) 50 (41–70) 0.137
FEV1, % predicted 57 (44–66) 44 (33–55) \0.0001
DLCO, % predicted 77 (63–88) 62 (46–79) 0.0007
Emphysema 56 (35) 26 (63) 0.0013
Chronic mucous hypersecretion 89 (56) 27 (66) 0.289
Chronic cor pulmonale 28 (18) 19 (46) 0.0003
Heart failure 13 (8) 10 (24) 0.010
Coronary artery disease 45 (28) 14 (34) 0.450
QoL questionnaire, total score 28 (19–46) 38 (24–63) 0.004
CRP (mg/L) 3.0 (1.4–6.6) 3.0 (1.3–9.1) 0.410
Inhaled bronchodilators 107 (67) 32 (78) 0.253
Inhaled corticosteroids 98 (62) 30 (73) 0.203
Statins 31 (19) 6 (15) 0.652
Differences between survived and died are assessed by Fisher exact test or Mood’s median test
QoL quality of life. For the other abbreviations see table 1
Intern Emerg Med
123
from other investigations [6–8], we evaluated a sample of
patients with moderate to severe COPD, and an equal-size
sample of controls that were matched to COPD patients on
age and gender. Cases and controls also featured very
similar prevalence of comorbid conditions.
Our results can be summarized as follows: (a) the crude
mortality rate in patients with moderate to severe COPD is
remarkably higher than that of controls sharing similar
comorbidities, (b) a high CRP level is a significant amplifier
of the risk of death only in patients with severe COPD so
that the hazard in this category is nearly tenfold that of
controls with a low CRP level, (c) the severity of airflow
obstruction, as reflected by FEV1, is a strong independent
predictor of reduced survival in COPD, (d) among the cases,
the rate of hospitalization for COPD exacerbation seems
more dependent on the severity of airway obstruction than
on the actual level of CRP.
With regard to the causes of death in our COPD sample,
13 (32%) of 41 were due to respiratory failure and 34% to
cardiovascular events, assuming that ‘‘sudden death’’ is
related to a major acute cardiovascular event. Cancer was
the cause of death in 17% of all deaths in COPD patients.
These figures are similar to those reported in the TORCH
study [25], where 27% of the deaths were deemed to be due
to cardiovascular causes, 35% to pulmonary causes, and
21% to cancer.
In the paper by Celli et al. [22], as many as 61% of the
deaths are attributed to respiratory failure. That study
comprised 635 patients with COPD from three different
countries (Spain, Venezuela, and the United States), most
of whom (71%) featured severe airflow obstruction [22].
In the study by Man et al. [7], the overall mortality rate
among the COPD patients is of only 6.8% during a median
period of 7.5 years of follow-up. The causes of death were
lung cancer (31%), cardiovascular diseases (26%), and
respiratory failure (8%). In the remaining 35%, the cause of
death was due to other illnesses. In that study, the mean
FEV1 was 78% of the predicted value [7]. Therefore, it is
quite reasonable that respiratory failure was the cause of
death in only a minority of the COPD patients.
In our sample, the COPD patients who died had more
severe airflow obstruction than those who survived (FEV1
44 vs. 57% of the predicted value), so it not surprising that
a substantial proportion of them died as a consequence of
respiratory failure.
Our study has some limitations. First, our sample was
smaller than that of other reports [6–8]. This precluded the
Table 4 Hazard ratio of death for different combinations of airflow
obstruction and C-reactive protein level
Category Hazard ratio 95% CI p value
Low CRP, no obstructiona 1.00 – –
High CRP, no obstruction 0.15 0.02–1.23 0.077
Low CRP, moderate obstruction 2.28 0.87–5.92 0.082
High CRP, moderate obstruction 1.08 0.35–3.32 0.887
Low CRP, severe obstruction 3.39 1.38–8.36 0.008
High CRP, severe obstruction 9.58 4.00–22.9 \0.0001
Low CRP: B3 mg/L; high CRP: [3 mg/L; moderate obstruction:
FEV1 between 50 and 69% predicted; severe obstruction: FEV1
\50% predicted
CI confidence interval, CRP C-reactive protein
a Reference category
Fig. 1 The cumulative rate of
death from any cause as a
function of CRP level and
degree of airflow obstruction in
200 COPD patients. Red line
high CRP level ([3 mg/L). Blue
line low CRP level (B3 mg/L).
Severe COPD, high versus low
CRP levels: log rank test,
p value 0.0228. Moderate
COPD, high versus low CRP
levels: log rank test, p value
0.1190
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possibility of investigating CRP levels as a predictor of
cause-specific mortality in COPD. Second, our follow-up
was shorter than that obtained by others [6–8]. Third, our
analysis was based on a single determination of CRP level
made at baseline. The latter limitation is shared by other
broad outcome studies [6–8].
Dahl et al. [8] report that a CRP level above 3 mg/L is
an independent predictor of future COPD-related hospi-
talization and death in a sample of 1,302 subjects with
airway obstruction selected from the Copenhagen City
Heart Study. The authors used a FEV1/FVC ratio of less
than 0.7 as the single criterion to select subjects for the
analysis, so it is unclear whether obstructive lung disorders
other than COPD were included in the sample.
Also, the 6% mortality rate reported by Dahl, during a
median duration of 8 years of follow-up, is far smaller than
that observed in our COPD sample (21%) over a shorter
period of follow-up.
In all likelihood, the subjects with airflow obstruction
recruited into population-based studies differ from the
COPD patients seen in the clinic. Therefore, the prognostic
value of an elevated CRP level, as assessed in epidemio-
logical surveys, may lose its strength when applied in
clinical practice.
Our findings are in agreement with those reported by de
Torres et al. [21] in 218 patients with moderate to very
severe COPD who were followed up for a median time of
3 years. In that study, the all-cause mortality rate is 25%,
which is very similar to that of our sample. The authors
find that CRP levels are not associated with survival and
that CRP does not add significant information to the risk
assessment provided by other tools such as the multidi-
mensional BODE index [22].
The interaction we observed between a high CRP level
and severe airflow obstruction may suggest that systemic
inflammation contributes to the determination of an
adverse outcome in patients with advanced COPD. Such an
interaction should be confirmed prospectively using serial
measurements of the CRP levels.
Elevated values of CRP are not specific to COPD inas
much as CRP increases in a variety of other inflammatory
disorders. So, CRP may be an inadequate marker to assess
the effect of any given therapeutic regimen on COPD-
related outcomes.
For example, some investigators report that inhaled
corticosteroids decrease CRP levels in patients with COPD
[4, 23]. We were unable to confirm this finding, and so do
others recently [24]. Anyway, there is no convincing evi-
dence, at present, that inhaled corticosteroids are effective
in reducing the all-cause mortality rate in COPD [25].
This should not be surprising, for COPD rarely occurs as
a single clinical entity. As many as 81% of the COPD
patients in our sample had at least one of cardiovascular,
metabolic or endocrine comorbidity.
It is quite clear, therefore, that COPD patients may
eventually die from conditions other than COPD. So, we
believe that the issue of comorbidity must be taken into
account while searching for new prognostic markers of
COPD.
In summary, our data indicate that a high CRP level is a
significant amplifier of the risk of death only in COPD
patients with severe airflow obstruction. Carefully designed
studies are, therefore, needed before endorsing CRP level
as an outcome predictor in patients with established COPD.
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